Analysts Set Grifols, S.A. (NASDAQ:GRFS) PT at $10.30

Grifols, S.A. (NASDAQ:GRFS) has been assigned an average recommendation of “Moderate Buy” from the six ratings firms that are covering the company, Marketbeat.com reports. Four investment analysts have rated the stock with a hold rating, one has issued a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among brokers that have covered the stock in the last year is $10.30.

GRFS has been the topic of a number of analyst reports. Wall Street Zen raised shares of Grifols from a “buy” rating to a “strong-buy” rating in a report on Monday, July 7th. Zacks Research raised shares of Grifols to a “hold” rating in a report on Friday, August 8th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Grifols in a report on Wednesday. JPMorgan Chase & Co. increased their price objective on shares of Grifols from $7.60 to $10.30 and gave the stock a “neutral” rating in a report on Tuesday, June 17th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of Grifols in a research report on Tuesday, August 5th.

Grifols Stock Up 0.4%

GRFS stock opened at $9.63 on Friday. The company has a quick ratio of 0.95, a current ratio of 2.64 and a debt-to-equity ratio of 1.20. Grifols has a fifty-two week low of $6.19 and a fifty-two week high of $11.14. The firm’s 50-day simple moving average is $10.08 and its 200 day simple moving average is $8.85. The stock has a market cap of $6.62 billion, a PE ratio of 8.23, a price-to-earnings-growth ratio of 0.33 and a beta of 0.69.

Grifols Dividend Announcement

The business also recently announced a special dividend, which was paid on Wednesday, August 20th. Investors of record on Tuesday, August 12th were given a $0.1404 dividend. The ex-dividend date was Tuesday, August 12th. Grifols’s dividend payout ratio is currently 11.97%.

Hedge Funds Weigh In On Grifols

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Corient Private Wealth LLC grew its position in Grifols by 81.0% in the 2nd quarter. Corient Private Wealth LLC now owns 57,416 shares of the biotechnology company’s stock valued at $519,000 after buying an additional 25,703 shares in the last quarter. Orion Porfolio Solutions LLC grew its position in Grifols by 83.5% in the 2nd quarter. Orion Porfolio Solutions LLC now owns 28,743 shares of the biotechnology company’s stock valued at $260,000 after buying an additional 13,075 shares in the last quarter. B. Riley Wealth Advisors Inc. bought a new position in Grifols in the 2nd quarter valued at about $438,000. State of Wyoming bought a new position in Grifols in the 2nd quarter valued at about $1,729,000. Finally, Grizzlyrock Capital LLC bought a new position in Grifols in the 2nd quarter valued at about $1,501,000.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.